JNJ-18038683 / J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JNJ-18038683 / J&J
NCT00566202: A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Completed
2a
67
US
Placebo, Escitalopram, JNJ-18038683
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
12/08
12/08
NCT02466685: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

Completed
2
60
US
JNJ-18038683, Placebo
Herbert Meltzer, Janssen Research & Development, LLC
Bipolar Disorder
 
 

Download Options